Designing Immunotherapies that Can Overcome Recurrence and Resistance

BioEclipse Therapeutics CEO Dr. Pam Contag, shares with Dan Levine, host of The Bio Report, about the ability of cancers to return after treatment with immunotherapies, BioEclipse’s efforts to develop a multi-mechanistic immunotherapy to overcome that challenge, and why its approach may have broad application across a range of cancers.